Drugs implicated in the development of subacute cutaneous lupus erythematosus

ACE inhibitors (captopril, cilazapril)

Antiarrhythmics (procainamide)

Antiseizure medications (phenytoin, lamotrigine)

Antifungals (griseofulvin, terbinafine)

Antihistamines (cinnarizine/thiethylperazine)

Antineoplastics (docetaxel, paclitaxel, anastrozole, gemcitabine, doxorubicin, tamoxifen, leuprorelin)

Beta blockers (acebutolol, oxprenolol)

Calcium channel blockers (diltiazem, nifedipine, nitrendipine, verapamil)

Diuretics (hydrochlorothiazide, spironolactone)

Immune modulators (leflunomide, interferon-alpha, interferon-beta)

Lipid-lowering agents (pravastatin, simvastatin)

NSAIDs (naproxen, piroxicam)

Proton pump inhibitors (omeprazole, lansoprazole, pantoprazole)

Sulfonylureas (glyburide)

TNF-alpha inhibitors (etanercept, infliximab, adalimumab, golimumab)

Others (D-penicillamine, bupropion, ticlopidine, ranitidine*)

ACE: angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs; TNF: tumor necrosis factor.

* Ranitidine has been withdrawn from the United States market.

Data from:

Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.
Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301:99.
Sheth N, Greenblatt D, Patel S, Acland K. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 2007; 32:593.
Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34:473.
Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2008; 158:628.
Wiechert A, Tuting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol 2008; 159:231.
Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146:1113.
Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol 2013; 149:1071.
Grönhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167:296.

Graphic 62265 Version 11.0